PharmacologyRisk Factors and Treatment of Clostridioides difficile in Pediatric PatientsNang, Catherine PharmD Author Information Catherine Nang, PharmD PGY-1 Pharmacy Resident, Kaiser Permanente Vallejo Medical Center, Vallejo, CA. The author declares no conflict of interest. Supplement digital content is available for this article. Direct URL citations are provided in the HTML and PDF versions of this article. Correspondence: Catherine Nang, PharmD, Kaiser Permanente Vallejo Medical Center, 975 Sereno Drive, Vallejo, CA 94589. E-mail: [email protected] Journal of Pediatric Surgical Nursing: 4/6 2022 - Volume 11 - Issue 2 - p 58-60 doi: 10.1097/JPS.0000000000000334 Buy SDC CME Test Metrics Abstract The purpose of this article is to discuss the pharmacological causes of pediatric Clostridioides difficile infection (CDI) and the treatment options available to clinicians. The authors identify antibiotic classes and antacids and how they interfere with normal gastrointestinal processes to cause CDI. In addition, the treatment algorithm for pediatric patients, which differs slightly from adults, is presented. Choosing the appropriate medication is imperative in reducing symptoms, recurrence, and optimizing treatment of CDI. This article will discuss the medications that contribute to CDI and not cover infectious causes or structural causes. Copyright © 2022 American Pediatric Surgical Nursing Association, Inc.